Altria Cannabis

Altria made a significant investment in Cronos Group, an innovative worldwide cannabinoid firm, in 2019. Cronos Group’s operations in the United States are exclusively limited to its hemp-derived CBD products while operating in the legal adult-use and medical THC cannabis markets outside the US. Cronos Group is working toward launching its adult-use THC cannabis business in the United States following nationwide legalization.

Altria supports a wide-ranging federal framework for all cannabis products, which is supported by science and evidence. The company believes that the firm is well-positioned to assist in the development of a responsible regulatory framework for CBD and THC due to extensive legislative and regulatory expertise in the U.S. that can result in a transparent, responsible, and equitable operating environment for cannabis commerce at the federal level.

The legality of CBD products in the United States is uncertain, despite their hemp-derived CBD having been removed from the Controlled Substances Act in 2018. Altria is lobbying for pro-consumer solutions to address the regulatory gaps surrounding the U.S. CBD market that are timely, comprehensive, and beneficial.